At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|November 10, 2022
Expert on PSMA-PET: "It's just simply better"
Author(s)Urology Times staff
"What we know for sure is [PSMA-PET is] just simply better imaging in terms of accuracy," says Ashley Ross, MD, PhD.
Advertisement
In this video, Ashley Ross, MD, PhD, associate professor of Urology and the clinical director of the Polsky Urologic Cancer Institute at Northwestern University, discusses the emergence of PSMA-PET in prostate cancer. Ross was speaking at the
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
4
Gedatolisib plus darolutamide shows preliminary activity in mCRPC
5